3 May 2018 - Novartis’ CAR-T therapy Kymriah will be available in the US to adults with relapsed large B-cell lymphoma – bringing the cell therapy into direct competition with Gilead’s rival at exactly the same price.

Kymriah (tisagenlecleucel) is also available in advanced paediatric B-cell precursor acute lymphoblastic leukaemia but in this first indication the Swiss pharma priced it at $475,000 with a money-back guarantee to hospitals if it does not work.

But in the new indication approved by the FDA Novartis has matched Gilead’s $373,000 price and does not offer any outcomes-based concessions.

Read Pharmaphorum article